This post hoc analysis aimed to assess the effects of SGLT2i-GLP-1RA combination therapy on BP control in patients with type 2 diabetes (T2D)
High), and mortality (Class IV
Understanding your peptide-pathway genetics reduces trial-and-error dosing, minimizes side effects, and identifies patients who may benefit from alternative weight loss strategies if standard GLP-1 therapy carries elevated risk
After 40 weeks, reduction of glycated hemoglobin (HbA1c) of -2.01, -2.24, -2.30 was seen in the 5 mg, 10 mg, and 15 mg tirzepatide respectively, compared to -1.86 reduction with 1 mg semaglutide
Each rat underwent an 18-day cycle during which they received the assigned injection every other daytotaling 8 injections over 15 daysto simulate onceweekly administration in human patients
Study Scope: Analyzed over 3,500 participants from STEP trials, finding similar mental health rates between semaglutide and placebo groups